Cancer Profiling Market Report 2026

Cancer Profiling Market Overview

• Cancer Profiling market size has reached to $15 billion in 2025 • Expected to grow to $25.62 billion in 2030 at a compound annual growth rate (CAGR) of 11.3% • Growth Driver: Rising Cancer Incidence Fuels Growth In Cancer Profiling Market • Market Trend: Technological Advancements in the Cancer Profiling Market to Enhance Precision Oncology • North America was the largest region in 2025.

What Is Covered Under Cancer Profiling Market?

Cancer profiling refers to a diagnostic procedure that is conducted to analyze the genetic information of tumor cells in the body. It provides information about certain molecular or genetic changes in a tumor, such as gene mutations or other changes in tumor DNA. The main technologies involved in cancer profiling are immunoassays, PCR (polymerized chain reaction), NGS (next-generation sequencing), microarrays, and in-situ hybridization. Immunoassays refer to laboratory tests that measure the concentration of a specific protein or other biomolecules in blood or urine samples. The genomic biomarkers and protein biomarkers are used for profiling various cancers including breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma cancer, and others for research applications, clinical applications, screening, diagnostics, prognostics, and others.

What Is The Cancer Profiling Market Growth Forecast?

The cancer profiling market size is expected to see rapid growth in the next few years. It will grow to $25.62 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to increasing demand for precision medicine approaches, expansion of companion diagnostics, growing use of liquid biopsy technologies, rising investments in oncology diagnostics, increasing integration of profiling in routine clinical workflows. Major trends in the forecast period include increasing adoption of ngs-based cancer profiling, rising use of comprehensive genomic panels, growing integration of ai in data interpretation, expansion of personalized oncology diagnostics, enhanced focus on early molecular detection.

Global Cancer Profiling Market Segmentation

1) By Technology: Immunoassays, PCR (Polymerized Chain Reaction), NGS (Next-Generation Sequencing), Microarrays, In-Situ Hybridization 2) By Biomarker Type: Genomic Biomarkers, Protein Biomarkers 3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancers 4) By Application: Research Applications, Clinical Applications, Diagnostics, Prognostics, Other Applications Subsegments: 1) By Immunoassays: Enzyme-Linked Immunosorbent Assay (ELISA), Western Blotting, Luminex xMAP Technology 2) By PCR (Polymerase Chain Reaction): Quantitative PCR (qPCR), Digital PCR (dPCR), Reverse Transcription PCR (RT-PCR) 3) By NGS (Next-Generation Sequencing): Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), Targeted Sequencing, RNA Sequencing (RNA-Seq) 4) By Microarrays: DNA Microarrays, RNA Microarrays, SNP Arrays 5) By In-Situ Hybridization: Fluorescence In-Situ Hybridization (FISH), Chromogenic In-Situ Hybridization (CISH)

What Is The Driver Of The Cancer Profiling Market?

The increasing incidence of cancer is expected to propel the growth of the cancer profiling market going forward. Incidence of cancer refers to the number of new cancer cases in a specific population for a given period. The increased incidence of cancer caused due to urbanization, a growing aging population, changing lifestyles, and environmental and genetic factors. Cancer profiling aids in the identification of specific molecular or genetic changes in a tumor, such as gene mutations or other changes in tumor DNA, which is helpful in the cancer treatment cycle. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2023, an estimated 165,000 Australians were newly diagnosed with cancer, which equates to over 450 cases each day, and males represented about 55% of these diagnoses. Therefore, the increasing incidence of cancer is driving the growth of the cancer profiling industry.

Key Players In The Global Cancer Profiling Market

Major companies operating in the cancer profiling market are Illumina Inc., Qiagen NV, NeoGenomics Inc., Sysmex Corporation, HTG Molecular Diagnostics Inc., Caris Life Sciences, NanoString Technologies Inc., Guardant Health Inc., Foundation Medicine Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Genscript Biotech Corporation, Tempus Labs Inc., Hologic Inc., Predictive Oncology Inc., Abbott Laboratories, Agilent Technologies Inc., PerkinElmer Inc., Siemens Healthineers, Genomic Health Inc., Natera Inc., ArcherDX Inc., Personal Genome Diagnostics Inc., Enzo Biochem Inc., Cancer Genetics Inc., OncoDNA SA, Ribomed Biotechnologies Inc., Biocartis Group NV, N-of-One Inc., Cynvenio Biosystems Inc., Inivata Ltd., Burning Rock Biotech Limited, PathAI Inc., GENEWIZ Inc., Genoptix Inc., OmniSeq Comprehensive, Resolution Bioscience, OncoCyte Corporation

Global Cancer Profiling Market Trends and Insights

Major companies operating in the cancer profiling market are focusing on technological advancements such as simultaneous whole-exome sequencing (WES) and whole-transcriptome sequencing (WTS) assays to provide more comprehensive, tissue-sparing, and clinically actionable molecular diagnostics for precision oncology. These assays combine DNA (exome) and RNA (transcriptome) analysis in a single workflow, enabling detection of genomic variants (like SNVs, indels, and copy-number alterations) alongside gene expression or fusion events, unlike traditional NGS tests that require separate assays or limited gene panels. For instance, in November 2024, Caris Life Sciences, a US-based precision medicine company, received FDA approval for MI Cancer Seek, an NGS in vitro diagnostic that performs WES and WTS simultaneously. The assay uses total nucleic acid (TNA) from FFPE tumor tissue to detect single-nucleotide variants, insertions or deletions across 228 genes, microsatellite instability (MSI), tumor mutational burden (TMB), and copy-number amplifications in breast cancer. By integrating DNA and RNA profiling in a single test, it preserves tissue, delivers clinically actionable companion diagnostic (CDx) indications across multiple tumor types, and accelerates therapy selection through a unified genomic blueprint.

What Are Latest Mergers And Acquisitions In The Cancer Profiling Market?

In January 2023, Agilent Technologies, a US-based biotechnology research company, acquired Avida Biomed Inc. for an undisclosed amount. This acquisition aims to enhance Agilent's capabilities in the field of molecular biology, particularly in developing innovative tools and technologies for synthetic biology applications. Avida Biomed Inc. is a US-based biotechnology research company.

Regional Outlook

North America was the largest region in the cancer profiling market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cancer Profiling Market?

The cancer profiling market consists of revenues earned by entities by providing services such as surgery, chemotherapy, radiotherapy, hormonal therapy, and immunotherapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. Cancer profiling also includes sales of diagnostic tests and spectrometers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cancer Profiling Market Report 2026?

The cancer profiling market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cancer profiling industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.